Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics has successfully raised $9.8 million through a combination of a $3 million placement and a $6.9 million share purchase plan. The funds will be used to advance the clinical development of PTX-100, a targeted cancer therapy, through Phase 2a trials, with the aim of progressing towards regulatory approval and addressing unmet medical needs in cancer treatment.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches for cancer treatment, including targeted and cellular therapies. One of its primary products is PTX-100, a first-in-class compound that inhibits the cancer growth enzyme GGT-1, disrupting oncogenic pathways and inducing cancer cell death. The company is also developing CellPryme-M, a technology to enhance adoptive cell therapy performance.
Average Trading Volume: 1,111,541
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$36.24M
For an in-depth examination of PTX stock, go to TipRanks’ Overview page.